Nevro - NVRO Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last year. There are currently 4 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 1-year price objectives for Nevro's stock. Their NVRO share price forecasts range from $31.00 to $95.00. On average, they predict the company's stock price to reach $54.58 in the next year. This suggests a possible upside of 48.8% from the stock's current price.
View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts.

Nevro's stock was trading at $39.60 at the start of the year. Since then, NVRO stock has decreased by 7.4% and is now trading at $36.68.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our NVRO earnings forecast.

Nevro will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings data on Wednesday, November, 2nd. The medical equipment provider reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. The medical equipment provider had revenue of $100.47 million for the quarter, compared to analyst estimates of $99.08 million. Nevro had a negative net margin of 2.01% and a negative trailing twelve-month return on equity of 40.89%.

Nevro updated its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $406.40 million-$406.40 million, compared to the consensus revenue estimate of $405.14 million.

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by many different retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.62%) and Exchange Traded Concepts LLC (0.09%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends.

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $36.68.

Nevro (NYSE:NVRO) has a market capitalization of $1.30 billion and generates $386.90 million in revenue each year. The medical equipment provider earns $-131,360,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

The company employs 945 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.